STATEMENT OF NEED
Breast cancer accounts for nearly 30% of cancer diagnoses among women in the United States, and is the second-leading cause of cancer death in this population. Although many women benefit from regular screening as well as earlier and improved treatment, approximately 10% present with metastatic disease, and 30% with no initial lymph node involvement eventually develop metastatic disease. Women with metastatic breast cancer (MBC) have a poorer prognosis than the overall population of breast cancer patients, and issues such as refractory or resistant disease, cumulative toxicities, adverse events, depression, and financial hardship are often encountered. Despite progress in understanding the pathogenesis of MBC and advances in therapy, the 5-year overall survival rate remains only 22%.
Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the management of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.
Upon completion of this activity, participants should be able to:
Constance Visovsky, PhD, RN, ACNP, FAAN
Associate Professor, College of Nursing
University of South Florida
Cynthia Cantril, RN, OCN®, CBCN®, MPH
Director of Cancer Support Services & Patient Navigation
Sutter Pacific Medical Foundation
Janice Famorca Tran, PhD, RN, MS, AOCNP®, CBCN®, ANP-C
Lynne Brophy, MSN, RN-BC, CNS, AOCN®
Breast Oncology Clinical Nurse Specialist
The Ohio State University
Theresa W. Gillespie, PhD, MA, RN
Professor, Department of Surgery and Department of Hematology & Medical Oncology
Emory University School of Medicine
There is no fee to participate in or claim CE credit for this activity.
Please note that the USF Health and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.
Jointly Provided by
USF Health is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.0 contact hour may be earned by learners who successfully complete this continuing nursing education activity.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 1 ILNA point toward:
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of CNE awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS WITH COMMERCIAL INTERESTS
USF Health and i3 Health endorse the standards of the ANCC that require everyone in a position to control the content of a CE activity to disclose all financial relationships with commercial interests that are related to the content of the CE activity. CE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. A conflict of interest is created when individuals in a position to control the content of CE have a relevant financial relationship with a commercial interest which, therefore, may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. USF Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. USF Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
Constance Visovsky, PhD, RN, ACNP, FAAN has no financial relationship(s) relevant to the content of this CE activity.
Cynthia Cantril, RN, OCN®, CBCN®, MPH has served on the speaker's bureau for Genentech.
Janice Famorca Tran, PhD, RN, MS, AOCNP®, CBCN®, ANP-C has no financial relationship(s) relevant to the content of this CE activity.
Lynne Brophy, MSN, RN-BC, CNS, AOCN® has no financial relationship(s) relevant to the content of this CE activity.
Theresa W. Gillespie, PhD, MA, RN has no financial relationship(s) relevant to the content of this CE activity.
Planning Committee, USF Health OCPD staff members, i3 Health staff members, and the peer/content reviewer for this activity have no relevant financial relationships to disclose.
Disclosures are on file at the USF Health Office of Continuing Professional Development.
No prerequisites are required for this activity.
REQUIREMENTS FOR CREDIT
Participants must sign-in before the start of the activity to verify attendance. All participants are asked to complete a pretest and a posttest for outcomes assessment; a passing score is not required. At the conclusion of the activity participants must complete an evaluation, attesting to the time spent in this live activity, claiming credit. Certificates of Completion will be emailed to participants within two weeks of the activity.
UNAPPROVED USE DISCLOSURE
USF Health and i3 Health require CE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
USF is an Equal Opportunity/Affirmative Action/Equal Access Institution.
This activity is supported by an independent educational grant from Lilly.